Current concepts in the pharmacotherapy of benign prostatic hyperplasia

References

• CAINE M: a-Adrenergic blockers for the treatment of benign prostatic hyperplasia. Urol. Clin. North Am. (1990) 17:641–649.
   PubMed Web of Science ®Google Scholar
• SCHWINN DA, MICHELOTTI GA: ai-Adrenergic receptors in the lower urinary tract and vascular bed: potential role for the aid subtype in filling symptoms and effects of ageing on vascular expression. BIU Int. (2000) 85(S2):6–11.
   Google Scholar
• MIZOBE T, MAZE M, LAM V, SURYANARAYANA S, KOBILKA B: Arrangement of transmembrane domains in adrenergic receptors. Similarity to bacteriorhodopsin. J. Biol. Chem. (1996) 271:2387–2389.
   PubMedGoogle Scholar
• GRAHAM RM, PEREZ DM, HWA J, PIASCIK MT: al-Adrenergic receptor subtypes: molecular structure, function, and signalling. Circ. Res. (1996) 78:737–749.
   PubMed Web of Science ®Google Scholar
• BERKOWITZ D, SCHWINN D: Basic pharmacology of a and fi adrenergic receptors. In: The Pharmacological Basis of Anesthesiology Bowdle KEA, Hotita A (Eds). Churchill Livingstone, Edinburgh, Scotland (1996):581–668.
   Google Scholar
• FORD APDW, ARREDONDO NE BLUE D Jr et al: RS-17053 (N-2-(2-cyclopropyl-methoxyphen- oxy)-5-chloro-a, a-dimethy1-1 H-indole-3-ethamine hydrochloride), a selective abodrenoceptor antagonist, displays low affinity for functional aradrenoceptors in human prostate: implications for adrenoceptor classification. Ma Pharmacol (1996) 49:209–215.
   PubMedGoogle Scholar
• FORD AP, DANIELS DV, CHANG DJ et al.: Pharmacological pleiotropism of the human recombinant abodrenoceptor: implications for aradrenoceptor classification. Br. J. Pharmacol (1997) 121:1127–1135.
   PubMed Web of Science ®Google Scholar
• HIEBLE JP, BYLUND DB, CLARKE DE et al.: International Union of Pharmacology. X. Recommendation of nomenclature of aradrenoceptors: consensus update. Pharmacol Rev (1995) 47:267–270.
   Google Scholar
• FORD APDW, WILLIAMS TJ, BLUE DR: al-Adrenoceptor classification: sharpening Occam's razor. TIPS (1994) 15:167–170.
   PubMedGoogle Scholar
• SCHWINN D, PAGES, MIDDLETON Jet al.: The a1-adrenergic receptor: characterization of signal transduction pathways and mammalian tissue heterogeneity. Ma Pharmacol (1991) 40:619–626.
   Google Scholar
• BERKOWITZ D, PRICE D, BELLO E, PAGE S, SCHWINN D: Localization of mRNA for three distinct a2-adrenergic receptor subtypes in human tissues: evidence for species heterogeneity and implications for human pharmacology. Anesthesiology (1994) 81:1235–1244.
   PubMed Web of Science ®Google Scholar
• HANSEN BJ, MEYHOFF HH, NORDLING J, MENSINK HJ, MOGENSEN P, LARSEN PH: Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. The ALFECH Study Group. Scandj Urol. Nephrol (1996) 30:373–377.
   PubMed Web of Science ®Google Scholar
• THIEN T, DELAERE KP, DEBRUYNE FM, KOENE RA: Urinary incontinence caused by prazosin. Br. Med. J. (1978) 1:622–623.
   PubMedGoogle Scholar
• •The first documented effect of a-adrenoceptor antagonists on the urinary tract.
   Google Scholar
• KIRBY RS, COPPINGER SW, CORCORAN MO, CHAPPLE CR, FLANNIGAN M, MILROY EJ: Prazosin in the treatment of prostatic obstruction. A placebo controlled study. Br. J. Urol. (1987) 60:136–142.
   PubMedGoogle Scholar
• CHAPPLE CR, CHRISTMAS TJ, MILROY EJ: A twelve-week placebo-controlled study of prazosin in the treatment of prostatic obstruction. Urol. Int. (1990) 45(S1):47–55.
   PubMedGoogle Scholar
• LE DUC A, CARIOU G, BARON C et al: A multicentre, double-blind, placebo-controlled trial on the efficacy of prazosin in the treatment of dysuria associated with benign prostatic hypertrophy. Urol. Int. (1990) 45(S1):56–62.
   PubMedGoogle Scholar
• CHAPPLE CR, STOTT M, ABRAMS PH, CHRISTMAS TJ, MILROY EJ: A 12-week placebo-controlled study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia. Br. J. Urol. (1992) 70:285–294.
   PubMedGoogle Scholar
• BANOS JE, BOSCH F, FARRE M: Drug induced priapism. Its aetiology, incidence and treatment. Med. Toxicol Adverse Drug Exp. (1989) 4:46–58.
   PubMedGoogle Scholar
• CHOW W, HAHN H, SANDHU D et al.: Multicentre controlled trial of indoramin in the symptomatic relief of benign prostatic hypertrophy. Br. J. [Rol (1990) 65:36–38.
   Google Scholar
• IACOVOU JVV, DUNN M: Indoramin - An effective new drug in the management of bladder outflow obstruction. Br. J. Urol. (1987) 60:526–528.
   PubMedGoogle Scholar
• STOTT MA, ABRAMS P: Indoramin in the treatment of prostatic bladder outflow obstruction. Br: J. Urol. (1991) 67:499–501.
   PubMedGoogle Scholar
• WILDE MI, FITTON A, MCTAVISH D: Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs (1993) 45:410–429.
   Google Scholar
• LUKACS B, BLONDIN P, MACCARTHY C, DU BB, GRIPPON P, LASSALE C: Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hyperplasia. Eur: Urol. (1996) 29:29–35.
   PubMed Web of Science ®Google Scholar
• •A multi-centre study suggesting that alfuzosin is well tolerated with no serious side effects.
   Google Scholar
• CARBIN BE, BAUER P, FRISKAND M, MOYSE D: Efficacy of alfuzosin (an aradrenoreceptor blocking drug) in benign hyperplasia of the prostate. Scand. Urol. Nephrol. Sapp]. (1991) 138:73–75.
   PubMedGoogle Scholar
• HANSEN BJ, NORDLING J, MENSINK HJ, WALTER S, MEYHOF HH: Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group. Scand. I Urol. Nephrol. Sapp]. (1994) 157:169–176.
   Google Scholar
• HANSEN BJ, FLYGER H, MORTENSEN S, MENSINK HJ, MEYHOF HH: Symptomatic outcome of transurethral prostatectomy, a-blockade and placebo in the treatment of benign prostatic hyperplasia. Evaluation of treatment with the Danish Prostatic Symptom Score (DAN-PSS-1) system. The ALFECH Study group. Scand. I Urol. Nephrol. (1996) 30:103–107.
   Google Scholar
• JARDIN A, BENSADOUN H, DELAUCHE-CAVALLIER MC, ATTALI P: Alfuzosin for treatment of benign prostatic hypertrophy. The BPHALF Group. Lancet (1991) 337:1457–1461.
   PubMed Web of Science ®Google Scholar
• •arAdrenoceptor antagonists produce rapid optimal flow rate, symptom improvement and full therapeutic benefit.
   Google Scholar
• MARTORANA G, GILBERTI C, DI SILVERIO F et al: Effects of short-term treatment with the arblocker alfuzosin on urodynamic pressure-flow parameters in patients with benign prostatic hyperplasia. Eur. Urol. (1997) 32:47–53.
   PubMedGoogle Scholar
• SCHULMAN CC, DE SY W, VANDENDRIS M, TOMAS M, SANTONI JP: Belgian multicentre clinical study of alfuzosin, a selective arblocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group. Acta Urol. Belg. (1994) 62:15–21.
   PubMedGoogle Scholar
• BUZELIN JM, ROTH S, GEFFRIAUD-RICOUARD C, DELAUCHE-CAVALLIER MC: Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. Eur: Urol. (1997) 31:190–198.
   Google Scholar
• TEILLAC P, DELAUCHE-CAVALLIER MC, ATTALI P: Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group. Br: J. Urol. (1992) 70:58–64.
   PubMedGoogle Scholar
• JARDIN A, BENSADOUN H, DELAUCHE-CAVALLIER MC, ATTALI P: Long-term treatment of benign prostatic hyperplasia with alfuzosin: A 12–18 month assessment. BPHALF Group. Br: J. Urol. (1993) 72:615–620.
   Google Scholar
• JARDIN A, BENSADOUN H, DELAUCHE-CAVALLIER MC, STALLA-BOURDILLON A, ATTALI P: Long-term treatment of benign prostatic hyperplasia with alfuzosin: A 24-30 month survey. BPHALF Group. Br. J. Urol. (1994) 74:579–584.
   PubMedGoogle Scholar
• SANCHEZ-CHAPADO M, GUIL M, ALFARO V, BADIELLA LL, FERNANDEZ-HERNANDO N: Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice. Eur: Urol. (2000) 37:421–427.
   PubMedGoogle Scholar
• VAN KERREBROECK P, JARDIN A, LAVAL KU: Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur. Urol. (2000) 37:306–313.
   Google Scholar
• VAN KERREBROEK P, JARDIN A, VAN CANGH P, LAVAL KU: Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur: Urol. (2002) 41(1):54–60.
   PubMedGoogle Scholar
• DJAVAN B, MARBERGER M: A meta-analysis on the efficacy and tolerability of aradrenoceptor antagonists in patients with lower urinary symptoms suggestive of benign prostatic obstruction. Eur: Urol. (1999) 36:1–13.
   PubMed Web of Science ®Google Scholar
• ••A comparison of the efficacy andtolerability of the main aradrenoceptor antagonists currently in use.
   Google Scholar
• LEPOR H, KAPLAN SA, KLIMBERG I: Doxazosin for benign prostatic hyperplasia: Long-term efficacy and safety in hypertensive and normotensive patients. Urol. (1997) 157:525–530.
   Google Scholar
• KIRBY RS: Profile of Doxazosin in the hypertensive man with benign prostatic hyperplasia. Br. J. Clin. Pratt. Suppl (1994) 74:23–28.
   PubMedGoogle Scholar
• ROEHRBORN CG, SIEGEL RL: Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology (1996) 48:406–415.
   PubMedGoogle Scholar
• LEPOR H, WILLIFORD WO, BARRY MJ et al.: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl. J. Med. (1996) 335:533–539.
   PubMed Web of Science ®Google Scholar
• •Multi-centre trial showing finasteride was not as effective as terazosin and that there was no role for combination therapy.
   Google Scholar
• ROEHRBORN CG, OESTERLING JE, AUERBACH S et al: The Hytrin Community Assessment Trial study: A one-year study of terazosin versus placebo in the treatment of men with benign prostatic hyperplasia. HYCAT Investigator Group. Urology (1996) 47:159–168.
   Google Scholar
• •Significant decrease in symptom score at 1 year with terazosin.
   Google Scholar
• KIRBY RS: Tetazosin in benign prostatic hyperplasia: effects of blood pressure in normotensive and hypertensive men. Br: J. Urol. (1998) 82:373–379.
   PubMedGoogle Scholar
• COOPER KL, MCKIERNAN JM, KAPLAN SA: a-Adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Drugs (1999) 57:9–17.
   PubMed Web of Science ®Google Scholar
• FURUKAWA K, ROSARIO DJ, SMITH DJ, CHAPPLE CR, UCHIYAMA T, CHESS-WILLIAMS R: cciA_Adrenoceptor-mediated contractile responses of the human vas deferens. Br. J. Pharmacol (1995) 116:1605–1610.
   PubMedGoogle Scholar
• Safety, efficacy and impact on patients' quality of life of a long-term treatment with the arblocker alfuzosin in symptomatic patients with BPH. The Italian Alfuzosin Co-operative Group. Eur. Urol. (2000) 37:680–686.
   Google Scholar
• CHUNG M, VASHI V, PUENTE J, SWEENEY M: Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br. J. Clin. Pharmacol (1999) 48:678–687.
   PubMed Web of Science ®Google Scholar
• ANDERSEN M, DAHLSTRAND C, HOYE K: Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur: Urol. (2000) 38(4):400–409.
   PubMedGoogle Scholar
• CHAPPLE CR, CARTER P, CHRISTMAS TJ et al.: A three month double-blind study of doxazosin as treatment for benign prostatic bladder obstruction. Br: J. Urol. (1994) 74:50–56.
   PubMedGoogle Scholar
• HOLME JB, CHRISTENSEN MM, RASMUSSEN PC et al.: 29-Week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia: a double-blind placebo-controlled study. Scand. Urol. Nephrol (1994) 28:77–82.
   PubMed Web of Science ®Google Scholar
• GILLENWATER JY, CONN RL, CHRYSANT SG et al.: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. Urol. (1995) 154:110–115.
   Google Scholar
• WILDE MI, FITTON A, SORKIN EM: Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs Ageing (1993) 3:258–277.
   Google Scholar
• LEPOR H, AUERBACH S, PURAS-BAEZ A et al: A randomised, placebo-controlled multicentre study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. Urol. (1992) 148:1467–1474.
   Web of Science ®Google Scholar
• DI SILVERIO F: Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy. Br. J. Urol. (1992) 70\(Suppl. 1):22–26.
   Google Scholar
• LLOYD SN, BUCKLEY JF, CHILTON CP, IBRAHIM I, KAISARY AV, KIRK D: Terazosin in the treatement of benign prostatic hyperplasia: a multicentre, placebo-controlled trial. Br. J. Urol. (1992) 70\(Suppl. 1):17–21.
   Google Scholar
• BRAWER MK, ADAMS G, EPSTEIN: Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. Arch. Fam. Med. (1993) 2:929–935.
   Google Scholar
• ELHILALI MM, RAMSEY EW, BARKIN J et al.: A multicentre, randomised, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology (1996) 47:335–342.
   PubMedGoogle Scholar
• WILDE MI, MCTAVISH D: Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs (1996) 52:883–898.
   Google Scholar
• FOGLAR R, SHIBATA K, HORIE K, HIRASAWA A, TSUJIMOTO G: Use of recombinant aradrenoceptors to characterise subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur: Pharmacol (1995) 288:201–207.
   PubMed Web of Science ®Google Scholar
• YAMADA S, TANAKA C, OKHURA T: High-affinity specific PH] tamsulosin binding to aradrenoceptors in human prostates with benign prostatic hypertrophy. Urol. Res. (1994) 22:273–278.
   PubMedGoogle Scholar
• •Identification of the uroselectivity of tamsulosin.
   Google Scholar
• NARAYAN P, TEWARI A: A second Phase III multicentre placebo-controlled study of 2 doses of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J. Urol. (1998) 160:1701–1706.
   Google Scholar
• LEPOR H: Phase III multicentre placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology (1998) 51:892–900.
   Google Scholar
• LEPOR H: Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of Phase III trial. Tamsulosin Investigator Group. Urology(1998) 51:901–906.
   Google Scholar
• NARAYAN P, LEPOR H: Long-term, open-label, Phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology (2001) 57(3):466–470.
   PubMedGoogle Scholar
• ABRAMS P, SPEAKMAN M, STOTT M, ARKELL D, POCOCK R: A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective am-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br.j Urol. (1997) 80:587–596.
   PubMedGoogle Scholar
• ABRAMS P, SCHULMAN CC, VAAGE S: Tamsulosin, a selective aie-adrenergic antagonist: a randomised, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Br. I Urol. (1995) 76:325–336.
   PubMedGoogle Scholar
• CHAPPLE CR, BAERT L, THIND P, HOFNERK, KHOE GS, SPANGBERG A: Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group. Eur. Urol. (1997) 32:462–470.
   Google Scholar
• CHAPPLE CR, WYNDAELE JJ, NORDLING J, BOEMINGHAUS F, YPMA AF, ABRAMS P: Tamsulosin, the first prostate-selective ccip-adrenoceptor antagonist. A meta-analysis of two randomised, placebo-controlled, multi-centre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur. Urol. (1996) 29:155–167.
   Google Scholar
• •Meta-analysis demonstrating tamsulosin 0.4 mg o.d. is safe, and improves symptom score and
   Google Scholar
• KAWABE K, UENO A, TAKIMOTO Y, ASO Y, KATO H: Use of an arblocker, YM617, in the treatement of benign prostatic hypertrophy. YM617 Clinical Study Group. J. Urol. (1990) 144:908–911.
   Google Scholar
• SCHULMAN CC, CORTVRIEND J, JONAS U, LOCK TM, VAAGE S, SPEAKMAN MJ: Tamsulosin, the first prostate-selective ccip-adrenoceptor antagonist. Analysis of a multinational, multi-centre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur: Urol. (1996) 29:145–154.
   Google Scholar
• MICHEL MC, BRESSEL HU, MEHLBURGER L, GOEPEL M: Tamsulosin: real life clinical experience in 19,365 patients. Eur: Urol. (1998) 34\(Suppl. 2):37–45.
   Google Scholar
• LOWE FC: Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: Pharmacodynamic effect. Ther. (1997) 19:730–742.
   PubMed Web of Science ®Google Scholar
• IMPERATO-MCGINLEY J, GUEVO L,GAUTERI T, PETERSON: Steroid 5-a reductase deficiency in a man: an inherited form of pseudohermaphroditism. Science (1974) 186:1213–1215.
   PubMed Web of Science ®Google Scholar
• PETERS CA, WALSH PC: The effect of nafarelin acetate, a luteinising hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl. J. Med. (1987) 317:599–604.
   PubMed Web of Science ®Google Scholar
• THE FINASTERIDE STUDY GROUP: Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate (1993) 22:291–299.
   PubMed Web of Science ®Google Scholar
• GORMLEY GJ, STONER E, BRUSKEWITZ RC et al.: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl. Med. (1992) 327:1185–1191.
   PubMed Web of Science ®Google Scholar
• ANDERSEN JT, EKMAN P, WOLF H et al.: Can finasteride reverse the process of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology(1995) 46:631–637.
   PubMed Web of Science ®Google Scholar
• •Finasteride reverses the natural progression of BPH.
   Google Scholar
• NICKEL JC, FRADER Y, BOAKE RC et al.: Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomised controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. Can. Med. Assoc. j (1996) 155:1251–1259.
   PubMedGoogle Scholar
• MCCONNELL JD, BRUSKEWITZ R, WALSH P et al.: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl. I Med. (1998) 338:557–563.
   PubMed Web of Science ®Google Scholar
• ••Large trial in North America showingfinasteride to be significantly effective at reducing the incidence of acute urinary retention and surgical intervention.
   Google Scholar
• BOYLE P, GOULD AL, ROEHRBORN CG: Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomised clinical trials. Urology (1996) 48:398–405.
   PubMed Web of Science ®Google Scholar
• MARBERGER MJ: Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled multicentre study. PROWESS Study Group. Urology (1998) 51:677–686.
   PubMed Web of Science ®Google Scholar
• EKMAN P: Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years. Follow-up of the Scandinavian Open-Extension Study. The Scandinavian Finasteride Study Group. Eur. Urol. (1998) 33:312–317.
   Google Scholar
• TENOVERJL, PAGANO GA, MORTON AS, LISS CL, BYRNES CA: Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: A primary care study. Clin. Ther. (1997) 19:243–258.
   PubMedGoogle Scholar
• STONER E: Three-year safety and efficacydata on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology (1994) 43:284–292.
   PubMed Web of Science ®Google Scholar
• WILTON L, PEARCE G, EDET E, FREEMANTLE S, STEPHENS MD, MANN RD: The safety of finasteride used in benign prostatic hypertrophy: A non-interventional observational cohort study in 14,772 patients. Br.j Urol. (1996) 78:379–384.
   PubMedGoogle Scholar
• ANDERSEN JT, NICKEL JC, MARSHALL VR, SCHULMAN CC, BOYLE P: Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology (1997) 49:839–845.
   PubMed Web of Science ®Google Scholar
• GUESS HA, ANDERSEN KE, GORMLEY GJ: The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate (1993) 22:31–37.
   PubMed Web of Science ®Google Scholar
• STONER E, ROUND E, FERGUSON D, GORMLEY GJ: Clinical experience of the detection of prostate cancer in patients with benign prostatic hyperplasia treated with finasteride. The Finasteride Study Group. Urol. (1994) 151:1296–1300.
   Google Scholar
• DEBRUYNE FMJ, JARDIN A, COLLOI D et al.: Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur: Urol. (1998) 34:169–175.
   PubMedGoogle Scholar
• THE MTOPS RESEARCH GROUP: The Impact of Medical Therapy on the Clinical Progression of BPH: Results of the MTOPS Trial. American Urological Association Annual Meeting. Orlando, FL, USA (2002).
   Google Scholar
• •A multi-centre trial demonstrating benefit from combination therapy with doxazosin and finasteride, than either drug alone.
   Google Scholar
• PEELING WB, ABRAMS P, RAMSEY JWA et al.: Double-blind placebo controlled study to evaluate the pharmacodynamic effect of SK&F 105657 in patients with benign prostatic hypertrophy. Proc. 10th Congr: Eur. Assoc. Urol. (1992) 240:148.
   Google Scholar
• ROEHRBORN CG, ANDRIOLE GL, NICKEL C, BOYLE P, RAMSDELL J, ROSENBLATT S: Effect of dutasteride, a novel dual 5a-reductase inhibitor, on BPH related signs and symptoms. American Urological Association Annual Meeting. Orlando, USA (2002).
   Google Scholar
• •The impact of a novel drug, recently licensed for use in the US.
   Google Scholar
• MOORE RJ, GAZAK JM, WILSON JD: Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 1713-estradiol. Clin. Invest. (1979) 63:351–357.
   Google Scholar
• RADLMAIER A, EICKENBERG HU, FLETCHER MS et al.: Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomised clinical trial using two doses of the aromatase inhibitor Atamestane. Prostate (1996) 29:199–208.
   PubMed Web of Science ®Google Scholar
• DENIS L, PAGANO F, ROBERTSON C et al.: Double-blind, randomised, placebo-controlled trial of mepartricin in the treatment of BPH. Um/. (1997) 157\(Suppl. 4):136:(Abstract 532).
   Google Scholar
• REECE SH, MEMON A, SMART CJ, DEWBURY K: The value of permixon in benign prostatic hypertrophy. Br. I Urol. (1986) 58(1):36–40.
   PubMedGoogle Scholar
• BRAEKMAN J, DENIS L, DEMETS DL et al.: A double-blind, placebo-controlled study of the plant extract Serenoa repens in the treatment of benign prostatic hyperplasia of the prostate. Eur: Clin. Res. (1997) 9:247–259.
   Google Scholar
• CHAMPAULT G, PATEL JC, BONNARD AM: A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br. I Clin. Pharmacol (1984) 18:461–462.
   PubMed Web of Science ®Google Scholar
• BELL R, ABRAMS P: The evidence-base for medical intervention. In: The Effective Management of Benign Prostatic Disease and Lower Urinary Tract Symptoms. McNicholas T, Kirby R, Miles A (Eds). Aesculapius Medical Press, London, UK (2000) Ch. 5: 79–98.
   Google Scholar
• WILT TJ, ISHANI A, STARK G, MACDONALD R, LAU J, MULROW C: Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review. JAMA (1998) 280:1604–1609.
   PubMed Web of Science ®Google Scholar
• •An extensive overview of saw palmetto therapy.
   Google Scholar
• DESCOTES JL, RAMBEAUD JJ, DESCHASEAUX P, FAURE G: Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin. Drug Invest. (1995) 9:291–297.
   Web of Science ®Google Scholar
• CARBIN BE, LARSSON B, LINDAHL 0: Treatment of benign prostatic hyperplasia with phytosterols. Br. Urol. (1990) 66:639–641.
   PubMedGoogle Scholar
• LEVIN RM, RIFFAUD JP, BELLAMY F et al.: Effects of tadenum pretreatment on bladder physiology and biochemistry secondary to partial outlet obstruction. Urol. (1996) 156:2084–2088.
   Google Scholar
• LEVIN RM, RIFFAUD JP, BELLAMY F et al.: Protective effect of tadenum on bladder function secondary to partial outlet obstruction. Urol. (1996) 155:1466–1470.
   Google Scholar
• YABLONSKY F, NICHOLAS V, RIFFAUD JP, BELLAMY F: Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts. Urol. (1997) 157:2381–2387.
   Google Scholar
• BERGES RR, WINDELER J, TRAMPISCH H, SENGE T: Randomised, placebo-controlled double-blind clinical trial of 13-sitosterol in patients with benign prostatic hyperplasia. Lancet (1995) 345:1529–1532.
   PubMed Web of Science ®Google Scholar
• BECKER H, EBELING L: Konservative therapie der benignen prostata-hyperplasie (BPH) mit Cernilton. Ur-0*e (1988) 28:301–306.
   Google Scholar
• BUCK AC, COX R, REES RWM, EBELING L, JOHN A: Treatment of outflow obstruction due to benign prostatic hyperplasia with the pollen extract Cernilton. Br.j Urol. (1990) 66:398–404.
   PubMedGoogle Scholar
• MACDONALD R, ISHANI A, RUTKS I, WILT TJ: A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. RIU Int. (2000) 85:836–841.
   Google Scholar